Search Result

Results for "

SSTRs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Somatostatin Receptor (54) CD3 (1) Dopamine Receptor (1) GHSR (1) Radionuclide-Drug Conjugates (RDCs) (3) Small Interfering RNA (siRNA) (15)
By Research Areas:	Cancer (18) Cardiovascular Disease (1) Endocrinology (10) Inflammation/Immunology (4) Metabolic Disease (13) Neurological Disease (10)
Oligonucleotides:	Pre-designed siRNA Sets (15) siRNAs (15)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Targets Recommended: Somatostatin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3124A

BIM-23190 hydrochloride	Somatostatin Receptor	Cancer
BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .

HY-105172

TT-232 CAP-232; TLN-232	Somatostatin Receptor	Inflammation/Immunology Cancer
TT-232 (CAP-232), a somatostatin derivative, is a peptide *SSTR1/SSTR4* agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .

HY-P3124

BIM-23190	Somatostatin Receptor	Cancer
BIM-23190, a somatostatin analog, a selective *SSTR2* and *SSTR5* agonist, exhibits K_i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual *SSTR2/SSTR5*-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to *SSTR2* and *SSTR5* (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-142699

SSTR4 agonist 2	Somatostatin Receptor	Inflammation/Immunology
SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107) .

HY-P4555

(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide	Somatostatin Receptor	Neurological Disease
(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analog with K_ds of 0.61, 11.05, 23.5, 1200 and >1000 nM for *SSTR5, SSTR3, SSTR2, SSTR1* and *SSTR4*, respectively .

HY-139347A

SSTR4 agonist-1 tartrate	Somatostatin Receptor	Others
SSTR4 agonist-1 tartrate (Preparation 4) is a *SSTR4* agonist .

HY-160176

SSTR5 antagonist 6	Somatostatin Receptor	Metabolic Disease
SSTR5 antagonist 6 is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with an IC₅₀ of 24 nM. SSTR5 antagonist 6 can be used in the study of type 2 diabetes .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of *SSTR₁₄, SSTR₂₅, and SSTR₂₈*. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of *SSTR₁₄, SSTR₂₅, and SSTR₂₈*. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-157303

SSTR5 antagonist 3	Somatostatin Receptor	Cardiovascular Disease
SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC₅₀ values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone .

HY-142700

SSTR4 agonist 3	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 3 is a potent agonist of *SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR*4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .

HY-142701

SSTR4 agonist 4	Somatostatin Receptor	Neurological Disease
SSTR4 agonist 4 is a potent agonist of *SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR*4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .

HY-P3618

Cortistatin-29 (reduced)	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀ values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-P2150

Cortistatin-29	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀ values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-163317

MMC(TMZ)-TOC	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC targets delivery of TMZ to SSTR2-positive tumor cells .

HY-P4100

*Cyclic SSTR* agonist octreotide**	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic Somatostatin Receptor *SSTR* agonist .

HY-RS13820

SSTR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
SSTR1 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR1 Human Pre-designed siRNA Set A SSTR1 Human Pre-designed siRNA Set A

HY-RS13821

Sstr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr1 Mouse Pre-designed siRNA Set A Sstr1 Mouse Pre-designed siRNA Set A

HY-RS13822

Sstr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr1 Rat Pre-designed siRNA Set A Sstr1 Rat Pre-designed siRNA Set A

HY-RS13823

SSTR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
SSTR2 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR2 Human Pre-designed siRNA Set A SSTR2 Human Pre-designed siRNA Set A

HY-RS13824

Sstr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr2 Mouse Pre-designed siRNA Set A Sstr2 Mouse Pre-designed siRNA Set A

HY-RS13825

Sstr2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr2 Rat Pre-designed siRNA Set A Sstr2 Rat Pre-designed siRNA Set A

HY-RS13826

SSTR3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
SSTR3 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR3 Human Pre-designed siRNA Set A SSTR3 Human Pre-designed siRNA Set A

HY-RS13827

Sstr3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr3 Mouse Pre-designed siRNA Set A Sstr3 Mouse Pre-designed siRNA Set A

HY-RS13828

Sstr3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr3 Rat Pre-designed siRNA Set A Sstr3 Rat Pre-designed siRNA Set A

HY-RS13829

SSTR4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
SSTR4 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR4 Human Pre-designed siRNA Set A SSTR4 Human Pre-designed siRNA Set A

HY-RS13830

Sstr4 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr4 Mouse Pre-designed siRNA Set A Sstr4 Mouse Pre-designed siRNA Set A

HY-RS13831

Sstr4 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr4 Rat Pre-designed siRNA Set A Sstr4 Rat Pre-designed siRNA Set A

HY-RS13832

SSTR5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
SSTR5 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SSTR5 Human Pre-designed siRNA Set A SSTR5 Human Pre-designed siRNA Set A

HY-RS13833

Sstr5 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr5 Mouse Pre-designed siRNA Set A Sstr5 Mouse Pre-designed siRNA Set A

HY-RS13834

Sstr5 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Somatostatin Receptor	Others
Sstr5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Sstr5 Rat Pre-designed siRNA Set A Sstr5 Rat Pre-designed siRNA Set A

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

HY-12819

MK-1421	Somatostatin Receptor	Metabolic Disease Endocrinology
MK-1421 is a potent and selective *sstr3* antagonist. MK-1421 regulates insulin secretion by binding to the *sstr3*. MK-1421 can be used in the research of type 2 diabetes .

HY-102037

SSTR5 antagonist 1	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC₅₀s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research .

HY-P5362

NODAGA-LM3	Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a *SSTR2* antagonist, and can be used for imaging of SSTR positive paragangliomas .

HY-114191

SSTR5 antagonist 2	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-114191A

SSTR5 antagonist 2 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) .

HY-P5362A

NODAGA-LM3 TFA	Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a *SSTR2* antagonist, and can be used for imaging of SSTR positive paragangliomas .

HY-159825

Branosotine	Somatostatin Receptor	Endocrinology
Branosotine is a potent agonist of somatostatin receptor (SSTR2), with the EC₅₀ of ＜0.1 nM .

HY-P2545

[Tyr1]-Somatostatin-14	Somatostatin Receptor	Endocrinology
[Tyr1]-Somatostatin-14 could binds to *SSTR2* .

HY-125382

L-797591	Somatostatin Receptor	Metabolic Disease
L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting *SSTR2* binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P10137

Satoreotide JR11	Somatostatin Receptor	Cancer
Satoreotide (JR11) is a *SSTR2* antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-13466

MK-4256 2 Publications Verification	Somatostatin Receptor	Metabolic Disease Endocrinology
MK-4256 is a potent and selective *SSTR3* antagonist with IC₅₀s of 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively.

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the *somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH)* secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

Cat. No.	Product Name	Target	Research Area